The global ophthalmic disease therapeutics market share in 2026 is witnessing steady expansion as the prevalence of glaucoma, dry eye disease, retinal diseases, allergies, and ocular infections continues to increase. Ophthalmic disease therapeutics include drugs and therapies used to manage a broad range of ocular conditions. Rising diagnosis rates, increasing healthcare expenditure, growing awareness of eye disorders, and continued development of innovative therapies are supporting market growth. The increasing number of regulatory approvals and product launches is also encouraging the adoption of ophthalmic treatments across developed and emerging markets.
According to Fortune Business Insights, the global ophthalmic disease therapeutics market size was valued at USD 40.09 billion in 2025. The market is projected to grow from USD 42.61 billion in 2026 to USD 71.58 billion by 2034, exhibiting a CAGR of 6.70% during the forecast period. North America dominated the global market with a share of 43.37% in 2025. The U.S. ophthalmic disease therapeutics market is projected to reach USD 25.72 billion by 2034, supported by rising approvals and the introduction of innovative therapies.
One of the notable trends shaping the ophthalmic disease therapeutics market is the increasing development of advanced drug delivery systems. The anatomy and physiology of the eye create challenges for conventional ocular drug delivery, encouraging pharmaceutical companies and research institutions to explore innovative approaches. Nanotechnology-based formulations, in situ gel technology, extended-release delivery methods, and other novel approaches are being investigated to improve drug bioavailability and ocular medication delivery.
The market is also witnessing increasing interest in novel therapies and differentiated treatment options. Partnerships and collaborations between pharmaceutical companies and research organizations are supporting the development of innovative therapies, including approaches involving gene therapies. The introduction of drug-eluting ophthalmic products represents another development in the market. In March 2022, Johnson & Johnson Services Inc. received U.S. FDA approval for ACUVUE Theravision with Ketotifen, described by Fortune Business Insights as the world's first and only drug-eluting contact lens.
The growing prevalence of ophthalmic disorders is a major factor supporting market expansion. Conditions such as glaucoma, retinal diseases, dry eye disease, and other ocular disorders are contributing to a growing patient population. The prevalence of several ophthalmic conditions is particularly significant among the geriatric population. Increasing awareness initiatives by healthcare agencies, governments, and market participants are also supporting higher diagnosis and treatment rates.
According to the Fortune Business Insights report, around 3.0 million Americans were suffering from glaucoma, including 2.7 million individuals aged 40 years or older, according to a 2020 American Academy of Ophthalmology article cited in the report. Rising healthcare expenditure and an increasing number of ophthalmologists in developed and emerging countries are further supporting demand for ophthalmic therapeutics.
Growing research and development activities are another important market driver. Pharmaceutical companies and research organizations are focusing on innovative drugs and therapies to address unmet treatment needs. Fortune Business Insights notes that around 44 pipeline candidates for macular degeneration were in Phase III clinical trials. The development and launch of new products are expected to support demand during the forecast period.
High costs associated with biologics and overall ophthalmic treatment can limit product adoption, particularly in emerging countries. Higher out-of-pocket spending and limited reimbursement can create barriers to treatment. The report cites treatment costs for certain anti-VEGF therapies and notes that affordability issues can contribute to treatment discontinuation. Lower awareness and limited diagnosis in some emerging countries also remain challenges for market expansion.
The ophthalmic disease therapeutics market comprises several established pharmaceutical companies offering prescription and over-the-counter products. Regeneron Pharmaceuticals Inc. holds a significant position due to sales of EYLEA in the U.S. and other markets and its investment in ophthalmic product research and development. In 2021, the company increased its R&D expenses for EYLEA by around 41.6% compared with the previous year.
Santen Pharmaceutical Co. Ltd. is also increasing its focus on product approvals, launches, strategic mergers and acquisitions, and research and development. In November 2022, Santen launched DIQUAS LX Ophthalmic Solution 3% in Japan for dry eye treatment. Other companies are investing in pipeline development and novel therapies to address the growing demand for ophthalmic disease treatments.